Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price reduced by Wells Fargo & Company from $1,050.00 to $900.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued research reports about the stock. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,037.33.
View Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Down 5.0 %
Hedge Funds Weigh In On Regeneron Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $39,000. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- How to Use Stock Screeners to Find Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Invest in Small Cap Stocks
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is the Dogs of the Dow Strategy? Overview and Examples
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.